Mark Coleman Biography and Net Worth

Director of Axsome Therapeutics

Dr. Coleman has been a member of our board of directors since December 2014.

In addition, from 2012 to 2014, Dr. Coleman served as a consultant to us. Dr. Coleman is currently President of National Spine and Pain Centers, LLC, or NSPC, the nation’s largest interventional pain management group and has served as the Medical Director of the Baltimore branch from 2005. Dr. Coleman served as Director of Novel Therapies at NSPC from 2009 to 2011. NSPC routinely evaluates emerging treatments for pain through the conduct of clinical trials. Dr. Coleman is a Diplomat of the American Board of Anesthesiology in Anesthesiology and Pain Management. Dr. Coleman holds an M.D. from Johns Hopkins University School of Medicine and received his undergraduate degree from Wesleyan University.

What is Mark Coleman's net worth?: The estimated net worth of Mark Coleman is at least $1.80 million as of May 28th, 2024. Dr. Coleman owns 19,848 shares of Axsome Therapeutics stock worth more than $1,800,809 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Coleman may own. Learn More about Mark Coleman's net worth.
How do I contact Mark Coleman?: The corporate mailing address for Dr. Coleman and other Axsome Therapeutics executives is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. Axsome Therapeutics can also be reached via phone at (212) 332-3241. Learn More on Mark Coleman's contact information.
Has Mark Coleman been buying or selling shares of Axsome Therapeutics?: Mark Coleman has not been actively trading shares of Axsome Therapeutics during the last quarter. Most recently, Mark Coleman sold 5,249 shares of the business's stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $75.21, for a transaction totalling $394,777.29. Following the completion of the sale, the director now directly owns 19,848 shares of the company's stock, valued at $1,492,768.08. Learn More on Mark Coleman's trading history.
Who are Axsome Therapeutics' active insiders?: Axsome Therapeutics' insider roster includes Mark Coleman (Director), Mark Jacobson (COO), Roger Jeffs (Director), Nick Pizzie (CFO), and Mark Saad (Director). Learn More on Axsome Therapeutics' active insiders.
Are insiders buying or selling shares of Axsome Therapeutics?: During the last twelve months, insiders at the sold shares 6 times. They sold a total of 126,552 shares worth more than $10,005,148.57. The most recent insider tranaction occured on September, 11th when Director Mark E Saad sold 11,016 shares worth more than $1,005,870.96. Insiders at Axsome Therapeutics own 22.4% of the company. Learn More about insider trades at Axsome Therapeutics.
Information on this page was last updated on 9/11/2024.

Mark Coleman Insider Trading History at Axsome Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/28/2024	Sell	5,249	$75.21	$394,777.29	19,848
9/15/2023	Sell	11,016	$75.19	$828,293.04	25,097
5/12/2021	Buy	500	$58.15	$29,075.00
6/29/2020	Buy	650	$78.50	$51,025.00
6/25/2019	Buy	400	$23.25	$9,300.00	653,048
5/13/2019	Buy	4,650	$21.44	$99,696.00	652,648
3/19/2019	Buy	5,100	$12.18	$62,118.00

Mark Coleman Buying and Selling Activity at Axsome Therapeutics

Axsome Therapeutics Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Today's Range

Now: $90.73

$87.69

$93.12

50 Day Range

MA: $93.65

$85.42

$100.49

2 Week Range

Now: $90.73

$64.11

$105.00

Volume

956,380 shs

Average Volume

610,942 shs

Market Capitalization

$4.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18

First JFK… next Elon?

From Porter & Company | Ad

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.